Avtor/Urednik     Bajuk-Studen, Katica; Šebeštjen, Miran; Pfeifer, Marija; Preželj, Janez
Naslov     Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome
Tip     članek
Vir     Eur J Endocrinol
Vol. in št.     Letnik 164, št. 3
Leto izdaje     2011
Obseg     str. 389-95
Jezik     eng
Abstrakt     Objective Accumulating evidence connects polycystic ovary syndrome (PCOS) with increased risk of cardiovascular disease. Endothelial dysfunction is present in PCOS and represents an early, reversible marker of cardiovascular damage. As androgens and renin-angiotensin-aldosterone system are implicated in the atherogenesis process of PCOS, we tested the hypothesis that treatment with spironolactone, an androgen and mineralocorticoid receptor blocking drug, might reverse endothelial dysfunction in PCOS. Patients A total of 30 non-obese PCOS patients, compared with 20 body mass index matched control subjects, were evaluated. PCOS patients were given spironolactone 100 mg daily in 21-day long intervals followed by a 7-day pause, for 6 months. Measurements Flow-mediated dilatation (FMD), glyceryl trinitrate-induced dilatation, free testosterone, androstenedione, DHEA-sulfate, total, low-density lipoprotein (LDL)-, high-density lipoprotein-cholesterol, and triglycerides were determined at baseline and after 6 months. Results Results are expressed as median (25-75th percentile). At baseline, FMD was significantly lower in PCOS patients than in controls: 6.0 (0.0-11.7) vs 10.2 (6.8-15.9) %, P=0.018. This difference disappeared after 6 months of spironolactone treatment, as FMD in PCOS patients significantly increased to 8.3 (5.7-10.3) %, P=0.034, and was no longer different from controls. In PCOS patients, serum androgen levels did not change during treatment, while total and LDL-cholesterol decreased significantly from 4.8 (4.1-5.1) mmol/l to 4.4 (3.9-4.8) mmol/l and from 2.5 (2.1-3.1) to 2.2. (2.1-2.5) mmol/l, P<0.05 and P<0.05 respectively. Conclusion Treatment with spironolactone normalized endothelial function and improved cholesterol levels in non-obese PCOS patients.
Deskriptorji     POLYCYSTIC OVARY SYNDROME
ENDOTHELIUM, VASCULAR
SPIRONOLACTONE
NITROGLYCERIN
BODY MASS INDEX
VASODILATION
TESTOSTERONE
ANDROSTENEDIONE
LIPOPROTEIN-X
DEHYDROEPIANDROSTERONE SULFATE